Tumor profiles identified known deleterious mutations in PTEN (p.Q245) and BRCA1 (p.E1038G), as well as a stop-gain mutation in BRIP1, and nonsynonymous mutations in BRCA2 and PALB2. All mutations were identified at both time points and nearly all regions. Here, PALB2 is linked to neoplasm.